Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jazz Pharma Plc
(NQ:
JAZZ
)
121.18
+0.38 (+0.31%)
Streaming Delayed Price
Updated: 3:19 PM EST, Dec 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Jazz Pharma Plc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements
December 09, 2024
The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and...
Via
Benzinga
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
November 27, 2024
Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.
Via
Benzinga
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
November 25, 2024
For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is a compelling option with its solid fundamentals.
Via
Chartmill
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
November 21, 2024
Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.
Via
Benzinga
Exposures
Product Safety
UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy
November 08, 2024
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
NASDAQ:JAZZ, an undervalued stock with good fundamentals.
November 04, 2024
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ): good value for what you're paying.
Via
Chartmill
In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals
October 23, 2024
Via
Benzinga
Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts
October 04, 2024
Via
Benzinga
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
November 06, 2024
CEO Bruce Cozadd emphasized that Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year.
Via
Benzinga
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
October 18, 2024
Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5!
Via
The Motley Fool
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
October 15, 2024
Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a...
Via
Benzinga
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
October 14, 2024
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals.
Via
Chartmill
FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms
September 19, 2024
Veterans: Epidiolex shows promise in treating Gulf War Illness, offering hope for those affected. Learn how it might benefit them.
Via
Benzinga
Despite its impressive fundamentals, NASDAQ:JAZZ remains undervalued.
September 19, 2024
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals.
Via
Chartmill
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
September 09, 2024
Via
Benzinga
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
August 19, 2024
Via
Benzinga
When you look at NASDAQ:JAZZ, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
August 29, 2024
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals.
Via
Chartmill
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
August 28, 2024
Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and...
Via
Benzinga
'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine
August 27, 2024
Via
Benzinga
The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal
August 23, 2024
Via
Benzinga
In a market where value is scarce, NASDAQ:JAZZ offers a refreshing opportunity with its solid fundamentals.
August 08, 2024
Don't overlook JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals
August 01, 2024
Via
Benzinga
How Is The Market Feeling About Jazz Pharmaceuticals?
July 15, 2024
Via
Benzinga
The 3 Best Cannabis Stocks to Buy in August 2024
August 05, 2024
Although cannabis stocks have been brutalized earlier, favorable legal winds could make the sector intriguing again.
Via
InvestorPlace
Topics
Cannabis
Exposures
Cannabis
3 Biotech Stocks to Buy on the Dip: July 2024
July 29, 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip.
Via
InvestorPlace
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
July 24, 2024
The companies are no longer developing their drug for essential tremor treatment.
Via
Investor's Business Daily
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
July 19, 2024
Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July.
Via
InvestorPlace
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
July 11, 2024
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Avicanna Exports Cannabinoids To Singapore Legally — Even Though Cannabis Is Punishable By Death In The Country
July 11, 2024
Cannabinoid-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) announced on Thursday that through its majority-owned subsidiary Santa Marta Golden Hemp the company...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
3 Mid-Cap Growth Rockets Trading at Deep Discounts to Their Potential
July 04, 2024
Large cap stocks are where the alpha is now, but there’s a case to be made for these undervalued mid-cap growth stocks
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.